Non Human Primate Core

核心B摘要 非人灵长类动物（NHP）核心旨在巩固NHP实验的监督和性能 标题为“RhCMV/SIV疫苗诱导的免疫学和病毒学基础”的计划项目的方案 复制逮捕效力”的结构化核心组成的经验丰富的研究人员。全球 核心的目标是提供领导和技术专长，以确保一致性和质量控制 在动物选择、研究方案的执行、实验程序的应用、动物观察 为实现项目和其他核心首席研究者的目标而进行的必要的数据收集。完成 因此，核心将管理和直接监督项目的所有NHP研究，包括：1）动物选择; 2)动物饲养和一般饲养; 3）实验程序和临床管理; 4）标本 收集和处理; 5）尸检研究;和6）动物人口统计学的获取和管理， 生理、临床和病理数据。该计划项目的总体目标是确定 在RhCMV/SIV中负责完全阻止和随后清除新生SIV感染的机制- 免疫的恒河猴，包括为了功效需要MHC-E限制性表位识别， 细胞如何介导复制停滞以及IL-15信号转导作为预测转录组学的作用 签名. NHP核心将提供所需的专业知识和技术支持，以确保成功 完成多方面和广泛的NHP研究协议，支持项目1 -免疫学和 RhCMV/SIV疫苗介导的SIV“复制停滞”功效的病毒学表征，项目2 - 疫苗接种后原发性SIV感染的体内T细胞（和总体免疫）拦截的表征 用差异响应程序化的RhCMV/SIV载体（MHC-E vs. MHC-II vs. MHC-Ia）和 常规SIV疫苗和项目3 -确定最小MHC-E限制性SIV表位靶向 RhCMV/SIV疫苗介导的SIV“复制停滞”功效所需的。

CORE B SUMMARY The Nonhuman Primate (NHP) Core seeks to consolidate supervision and performance of the NHP experimental protocols of the Program Project entitled “Immunologic and virologic basis of RhCMV/SIV vaccine-induced replication arrest efficacy” into a structured Core composed of highly experienced research personnel. The global objective of the Core is to provide leadership and technical expertise to ensure consistency and quality control in animal selection, execution of study protocols, application of experimental procedures, animal observations and data collection necessary to meet the objectives of Project and other Core lead investigators. To accomplish this, the Core will manage and directly supervise all NHP studies for the Project including: 1) animal selection; 2) animal housing and general husbandry; 3) experimental procedures and clinical management; 4) specimen collection and processing; 5) necropsy studies; and 6) acquisition and management of animal demographic, physiologic, clinical, and pathologic data. The overall objective of the Program Project is to determine the mechanisms responsible for complete arrest and subsequent clearance of nascent SIV infection in RhCMV/SIV- immunized rhesus macaques, including the requirement for MHC-E restricted epitope recognition for efficacy, how cells mediate replication arrest and the role of IL-15 signaling identified as a predictive transcriptomic signature. The NHP Core will provide the expertise and technical support required to insure successful completion of the multifaceted and extensive NHP research protocols supporting Project 1 – Immunologic and virologic characterization of RhCMV/SIV vaccine-mediated SIV “replication arrest” efficacy, Project 2 – Characterization of the in vivo T cell (and overall immune) interception of primary SIV infection after vaccination with differentially response programmed RhCMV/SIV vectors (MHC-E vs. MHC-II vs. MHC-Ia) and a conventional SIV vaccine, and Project 3 – Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV “replication arrest” efficacy.